Cargando…
BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694
BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The res...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213312/ http://dx.doi.org/10.1093/noajnl/vdz014.017 |
_version_ | 1783531777328939008 |
---|---|
author | Huff, Wei Shireman, Jack Monaco, Gina Agrawal, Namita Park, Cheol Saathoff, Miranda Henriquez, Mario Watson, Gordon Ahmed, Atique Dey, Mahua |
author_facet | Huff, Wei Shireman, Jack Monaco, Gina Agrawal, Namita Park, Cheol Saathoff, Miranda Henriquez, Mario Watson, Gordon Ahmed, Atique Dey, Mahua |
author_sort | Huff, Wei |
collection | PubMed |
description | BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The resected tumor was divided into two groups: ‘center’ and ‘periphery’ with respect to the center of SRS treatment with periphery within 50%-isodose-line. Tissue was analyzed by whole exome sequencing (WES) and compared between the two groups as well as to non-radiated control tissues. RESULTS: All sequenced samples contained greater than 95% clean reads with an average read density of 100 base pairs and mapping efficiency of >99%. Preliminary analysis focused on SNP and Indel detection. In pooled groups with n=7 replicates there was no statistically significant differences in total mutation burden in either SNP’s or Indels compared between controls and both treatment locations. Delving deeper intronic, frameshift, missense, and nonsense mutations all also showed insignificant changes between controls and center or peripheral tumor locations (p >0.5, p >0.1, p >0.4, p >0.3 respectively) hinting that at a pooled biological level there are not significant mutational burdens between treatment locations. However, at the individual level, matched comparison of SRS samples originating from the center or periphery of the same tumor showed total mutational burden differences. 6 out of 7 (86%) patients showed decreased total number of indels in peripheral vs. center and 5 out of 7 (71%) patients showed decreased number of SNP’s in peripheral vs. center locations. CONCLUSION: Ultimately, these data demonstrate the power of matched patient controls over bulk analysis in order to elucidate smaller but possibly biologically meaningful effects, and point to a possible location dependency in treatment associated mutation burden within a single patient and single tumor that may be masked at a population level. |
format | Online Article Text |
id | pubmed-7213312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72133122020-07-07 BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 Huff, Wei Shireman, Jack Monaco, Gina Agrawal, Namita Park, Cheol Saathoff, Miranda Henriquez, Mario Watson, Gordon Ahmed, Atique Dey, Mahua Neurooncol Adv Abstracts BACKGROUND: Stereotactic radiosurgery (SRS) is an increasingly common modality used with or without surgery for brain metastases (BM). However, biological effect of SRS to tumors in vivois not known. METHODS: Patients were treated with SRS prior to surgery as per the clinical trial protocol. The resected tumor was divided into two groups: ‘center’ and ‘periphery’ with respect to the center of SRS treatment with periphery within 50%-isodose-line. Tissue was analyzed by whole exome sequencing (WES) and compared between the two groups as well as to non-radiated control tissues. RESULTS: All sequenced samples contained greater than 95% clean reads with an average read density of 100 base pairs and mapping efficiency of >99%. Preliminary analysis focused on SNP and Indel detection. In pooled groups with n=7 replicates there was no statistically significant differences in total mutation burden in either SNP’s or Indels compared between controls and both treatment locations. Delving deeper intronic, frameshift, missense, and nonsense mutations all also showed insignificant changes between controls and center or peripheral tumor locations (p >0.5, p >0.1, p >0.4, p >0.3 respectively) hinting that at a pooled biological level there are not significant mutational burdens between treatment locations. However, at the individual level, matched comparison of SRS samples originating from the center or periphery of the same tumor showed total mutational burden differences. 6 out of 7 (86%) patients showed decreased total number of indels in peripheral vs. center and 5 out of 7 (71%) patients showed decreased number of SNP’s in peripheral vs. center locations. CONCLUSION: Ultimately, these data demonstrate the power of matched patient controls over bulk analysis in order to elucidate smaller but possibly biologically meaningful effects, and point to a possible location dependency in treatment associated mutation burden within a single patient and single tumor that may be masked at a population level. Oxford University Press 2019-08-12 /pmc/articles/PMC7213312/ http://dx.doi.org/10.1093/noajnl/vdz014.017 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Huff, Wei Shireman, Jack Monaco, Gina Agrawal, Namita Park, Cheol Saathoff, Miranda Henriquez, Mario Watson, Gordon Ahmed, Atique Dey, Mahua BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title | BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title_full | BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title_fullStr | BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title_full_unstemmed | BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title_short | BSCI-19. EFFECT OF STEREOTACTIC RADIOSURGERY ON NON-SMALL CELL LUNG CANCER BRAIN METASTASIS: CORRELATIVE RADIOBIOLOGIC ANALYSIS FROM PHASE-II CLINICAL TRIAL NCT03398694 |
title_sort | bsci-19. effect of stereotactic radiosurgery on non-small cell lung cancer brain metastasis: correlative radiobiologic analysis from phase-ii clinical trial nct03398694 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213312/ http://dx.doi.org/10.1093/noajnl/vdz014.017 |
work_keys_str_mv | AT huffwei bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT shiremanjack bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT monacogina bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT agrawalnamita bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT parkcheol bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT saathoffmiranda bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT henriquezmario bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT watsongordon bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT ahmedatique bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 AT deymahua bsci19effectofstereotacticradiosurgeryonnonsmallcelllungcancerbrainmetastasiscorrelativeradiobiologicanalysisfromphaseiiclinicaltrialnct03398694 |